HMSA Commercial plans cover immunizations in accordance with the recommendations of the Advisory Committee on Immunization Practices (ACIP).
ACIP Recommendations
The Advisory Committee on Immunization Practices (ACIP) develops vaccine recommendations for children and adults. The recommendations include the age(s) when the vaccine should be given, the number of doses needed, the amount of time between doses, and precautions and contraindications.
COVID-19 Vaccine and Vaccine Administration codes. For commercial members, as of 09/12/2023, COVID-19 vaccines will be commercially available and covered by HMSA. Coverage is limited to the administration codes, see COVID-19 Immunization Administration codes.
Chikungunya virus vaccine, live attenuated, for intramuscular use
Chikungunya
90593
Chikungunya virus vaccine, recombinant, for intramuscular use
Chikungunya
90625
Cholera vaccine, live, adult dosage, 1 dose schedule, for oral use
Cholera
90683
Respiratory syncytial virus vaccine, mRNA lipid nanoparticles, for intramuscular use
Respiratory Syncytial Virus (RSV)
90690
Typhoid vaccine, live, oral
Typhoid
91304
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanparticle, saponin-based adjuvant, 5 mcg/0.2 mL dosage, for intramuscular use
COVID-19 vaccine - Novavax
91318
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use
COVID-19 vaccine – Pfizer-BioNTech
91319
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use
91320
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use
91321
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use
COVID-19 - Moderna
91322
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use
91323
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 10 mcg/0.2 mL dosage, for intramuscular use
90584
Dengue vaccine, quadrivalent, live, 2 dose schedule, for subcutaneous use
Dengue
90587
Dengue vaccine, quadrivalent, live, 3 dose schedule, for subcutaneous use
90696
Diphtheria, tetanus toxoids, acellular pertussis vaccine and inactivated poliovirus vaccine, when administered to children 4 through 6 years of age, for intramuscular use
Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine, for intramuscular use
Diphtheria, Tetanus, Pertussis, Poliovirus, Haemophilus Influenzae type B, and Hepatitis B (DTaP-IPV-Hib-HepB)
90698
Diphtheria, tetanus toxoids, acellular pertussis vaccine, Haemophilus influenzae type b, and inactivated poliovirus vaccine, for intramuscular use
Diphtheria, Tetanus, Pertussis, Poliovirus, and Haemophilus influenzae type B (DTaP-IPV/Hib)
90700
Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than 7 years, for intramuscular use
Diphtheria, Tetanus, and Pertussis (DTaP)
90702
Diphtheria and tetanus toxoids adsorbed when administered to individuals younger than 7 years, for intramuscular use
Diphtheria and Tetanus (DT)
90723
Diphtheria, tetanus toxoids, acellular pertussis vaccine, hepatitis B, and inactivated poliovirus vaccine, for intramuscular use
Diphtheria, Tetanus, Pertussis , Hepatitis B, and Poliovirus (DTaP-HepB-IPV)
90758
Zaire ebolavirus vaccine, live, for intramuscular use
Ebolavirus
90647
Haemophilus influenzae type b vaccine, PRP-OMP conjugate, 3 dose schedule, for intramuscular use
Haemophilus influenzae type b (Hib)
90648
Haemophilus influenzae type b vaccine (Hib), PRP-T conjugate, 4 dose schedule, for intramuscular use
90632
Hepatitis A vaccine (HepA), adult dosage, for intramuscular use
Hepatitis A
90633
Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use
90634
Hepatitis A vaccine (HepA), pediatric/adolescent dosage-3 dose schedule, for intramuscular use
90636
Hepatitis A and hepatitis B vaccine (HepA-HepB), adult dosage, for intramuscular use
Hepatitis A and Hepatitis B
90739
Hepatitis B vaccine (HepB), CpG-adjuvanted, adult dosage, 2 dose or 4 dose schedule, for intramuscular use
Hepatitis B
90740
Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 3 dose schedule, for intramuscular use
90743
Hepatitis B vaccine (HepB), adolescent, 2 dose schedule, for intramuscular use
90744
Hepatitis B vaccine (HepB), pediatric/adolescent dosage, 3 dose schedule, for intramuscular use
90746
Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use
90747
Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 4 dose schedule, for intramuscular use
90759
Hepatitis B vaccine (HepB), 3-antigen (S, Pre-S1, Pre-S2), 10 mcg dosage, 3 dose schedule, for intramuscular use
90748
Hepatitis B and Haemophilus influenzae type b vaccine, for intramuscular use
Hepatitis B and Haemophilus influenzae type b (Hib-HepB)
90649
Human Papillomavirus vaccine, types 6, 11, 16, 18, quadrivalent (4vHPV), 3 dose schedule, for intramuscular use
Human Papillomavirus Virus
90650
Human Papillomavirus vaccine, types 16, 18, bivalent (2vHPV), 3 dose schedule, for intramuscular use
90651
Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use
90630
Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, for intradermal use
Influenza
90653
Influenza vaccine, inactivated (IIV), subunit, adjuvanted, for intramuscular use
90654
Influenza virus vaccine, trivalent (IIV3), split virus, preservative-free, for intradermal use
90655
Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.25 mL dosage, for intramuscular use
90656
Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use
90657
Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use
90658
Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use
90660
Influenza virus vaccine, trivalent, live (LAIV3), for intranasal use
90661
Influenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use
90662
Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use
90672
Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use
90673
Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use
90674
Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use
90682
Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use
90685
Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL, for intramuscular use
90686
Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use
90687
Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.25 mL dosage, for intramuscular use
90688
Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use
90689
Influenza virus vaccine, quadrivalent (IIV4), inactivated , adjuvanted, preservative, preservative free, 0.25 mL dosage, for intramuscular use
90694
Influenza virus vaccine, quadrivalent (aIIV4), inactivated, adjuvanted, preservative free, 0.5 mL dosage, for intramuscular use
Q2034
Influenza virus vaccine, split virus, for intramuscular use (Agriflu)
Q2035
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (AFLURIA)
Q2036
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (FLULAVAL)
Q2037
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (FLUVIRIN)
Q2038
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (Fluzone)
90738
Japanese encephalitis virus vaccine, inactivated, for intramuscular use
Japanese Encephalitis
90707
Measles, mumps and rubella virus vaccine, live, for subcutaneous use
Measles, Mumps, Rubella (MMR)
90710
Measles, mumps, rubella, and varicella vaccine, live, for subcutaneous use
Measles, Mumps, Rubella and Varicella (MMRV)
90623
Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y-tetanus toxoid carrier, and Men B-FHbp, for intramuscular use
Meningococcal (MENACWY-TT MENB-FHBP)
90624
Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y-tetanus toxoid carrier, and Men B-FHbp, for intramuscular use
Meningococcal
90619
Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier, for intramuscular use
Meningococcal and Tetanus (MENACWY-TT)
90620
Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B, 2 dose schedule, for intramuscular use
Meningococcal (MenB-4C)
90621
Meningococcal recombinant lipoprotein vaccine, serogroup B, 2 or 3 dose schedule, for intramuscular use
Meningococcal (MenB-FHbp)
90644
Meningococcal conjugate vaccine, serogroups C & Y and Haemophilus influenzae type B vaccine, 4 dose schedule, when administered to children 6 weeks-18 months of age, for intramuscular use
Meningococcal and Haemophilus influenzae type B (Hib-MENCY)
90733
Meningococcal polysaccharide vaccine serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier or CRM197 carrier, for intramuscular use
Meningocococcal Polysaccharide (MPSV4)
90734
Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier or CRM197 carrier (MenACWY-CRM), for intramuscular use
Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use
Pneumococcal conjugate
90671
Pneumococcal conjugate vaccine, 15 valent (PCV15), for intramuscular use
90677
Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use
90684
Pneumococcal conjugate vaccine, 21 valent (PCV21), for intramuscular use
90732
Pneumococcal polysaccharide vaccine, 23-valent, adult or immunosuppressed patient dosage, when administered to individuals 2 years or older, for subcutaneous or intramuscular use
Pneumococcal polysaccharide (PPSV23)
90713
Poliovirus vaccine, inactivated, for subcutaneous or intramuscular use
Poliovirus (IPV)
90380
Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use
Respiratory Syncytial Virus (RSV)
90381
Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use
90382
Respiratory syncytial virus, monoclonal antibody, seasonal dose, 0.7 mL, for intramuscular use
90678
Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use
90679
Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use
90680
Rotavirus vaccine, pentavalent, 3 dose schedule, live, for oral use
Rotavirus (RV5)
90681
Rotavirus vaccine, human, attenuated, 2 dose schedule, live, for oral use
Rotavirus (RV1)
90714
Tetanus and diphtheria toxoids adsorbed (Td), preservative free, when administered to individuals 7 years or older, for intramuscular use
Tetanus and diphtheria (Td)
90715
Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use
Tetanus, Diphtheria, and Pertussis (Tdap)
90626
Tick-borne encephalitis virus vaccine, inactivated; 0.25 mL dosage, for intramuscular use
Tick-borne encephalitis
90627
Tick-borne encephalitis virus vaccine, inactivated; 0.5 mL dosage, for intramuscular use
90691
Typhoid vaccine, Vi capsular polysaccharide, for intramuscular use
Typhoid (ViCPs)
90716
Varicella virus vaccine, live, for subcutaneous use
Varicella (VAR
90717
Yellow fever vaccine, live, for subcutaneous use
Yellow fever
90736
Zoster (shingles) vaccine, live, for subcutaneous injection
Zoster (HZV)
90750
Zoster (shingles) vaccine, recombinant, subunit, adjuvanted, for intramuscular use
Vaccine Administration Codes
Code
Long Description
Used for
90460
Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered
0 through 18 years; first or only component of each vaccine or toxoid administered
90461
Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; each additional vaccine or toxoid component administered (List separately in addition to code for primary procedure)
0 through 18 years; each additional vaccine or toxoid component administered
90471
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)
1 vaccine (single or combination vaccine/toxoid)
90472
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure)
Each additional vaccine (single or combination vaccine/toxoid)
90473
Immunization administration by intranasal or oral route; 1 vaccine (single or combination vaccine/toxoid)
Administration by intranasal or oral route; 1 vaccine (single or combination vaccine/toxoid)
90474
Immunization administration by intranasal or oral route; each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure)
Administration by intranasal or oral route; each additional vaccine (single or combination vaccine/toxoid)
90480
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, single dose
Administration of respiratory syncytial virus, monoclonal antibody, seasonal dose by intramuscular injection, with counseling by physician or other qualified health care professional
Respiratory Syncytial Virus administration code (i.e. used with 90380 or 90381)
96381
Administration of respiratory syncytial virus, monoclonal antibody, seasonal dose by intramuscular injection
G0008
Administration of influenza virus vaccine
G0009
Administration of pneumococcal vaccine
G0010
Administration of hepatitis B vaccine
The original monovalent vaccines' emergency use authorization (EUA) has been rescinded and those vaccines are no longer recommended for use, effective November 1, 2023
• Please be sure to use the most up-to-date industry-standard procedure, revenue, and diagnosis codes from the current CPT ®′′, HCPCS Level II, and ICD-10-CM manuals, as recommended by the American Medical Association (AMA), the Centers for Medicare & Medicaid Services (CMS), and the American Hospital Association.
♣ Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently.
Claim Billing Examples • ♦
♦ CPT, diagnosis codes and ACIP recommendations are subject to change and are used as reference examples only.
EXAMPLE 1
ACIP Hepatitis B recommendation state “all adults requesting protection from HBV infection, without requiring them to acknowledge a specific factor” should be vaccinated. Adult member presents to a physician office requesting the Hepatitis B vaccination. The adult member does not disclose a specific risk factor and is not required.
Diagnosis:
Z23 - Encounter for immunization
Code:
90746 - Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use
90471 – Immunization Administration
Modifier:
No modifier necessary
EXAMPLE 2
ACIP Hepatitis A recommendation states “persons with end-stage renal disease, including predialysis, hemodialysis, peritoneal dialysis, and home dialysis patients” should be vaccinated. Adult member presents to a physician office for Hepatitis A vaccine because the member is considered a high risk candidate due to End Stage Renal Disease.
Diagnosis:
N18.6 - End stage renal disease
Z99.2 - Dependence on renal dialysis
Z23 - Encounter for immunization
Code:
90632 - Hepatitis A vaccine (HepA), adult dosage, for intramuscular use
Append modifier SK
90471 – Immunization Administration
Modifier:
SK - Member of high risk population (use only with codes for immunization)
EXAMPLE 3
ACIP recommendation states, “pregnant people during 32 through 36 weeks gestation, using seasonal administration, to prevent RSV lower respiratory tract infection in infants” should be vaccinated. Member informs physician or other qualified healthcare professional provider that they are 33 weeks gestation.
Diagnosis:
Z23 - Encounter for immunization
Z3A.33 - 33 weeks gestation of pregnancy
Code:
90678 – Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use
90471 – Immunization Administration
Additional Billing Information • ♣ ♦
Bill the procedure code(s) representing the vaccine/toxoid and the appropriate administration code (s) on the same claim.
HMSA prefers that a provider bills administration codes on a single line with a count (# of units).
HMSA does not pay for vaccines provided by the State. Vaccines provided by the state should append modifier SL (State supplied vaccine) on the vaccine claim line with a nominal bill charge of $0.00. Note: IF system is limited and a charge is required, bill charge at $0.01.
We encourage billing the COVID -19 vaccine & vaccine administration separately from other services rendered in the same visit.
During the public health emergency (PHE) period, COVID-19 vaccines are funded by the federal government. Therefore, you are not required to bill for the COVID-19 vaccines (CPT 91300, 91301, or 91303).
According to Noridian, UB claims billed for COVID-19 vaccine administration shall be billed with revenue code 0771 (Preventive Care Services – Vaccine Administration). Using other revenue codes may result to bundling into a case rate.
Report CPT codes 90460 and 90461 only when the physician or other qualified healthcare professional provides face-to-face counseling to the patient/family during the vaccine administration.
Code 90460 is reported once for the first component of each vaccine or toxoid administered by any route.
Code 90461 is additionally reported for the counseling associated with each additional component of any combination vaccine or toxoid.
A component refers to all antigens in a vaccine that prevents disease(s) caused by one organism. Multivalent antigens or multiple serotypes of antigens against a single organism are considered a single component of vaccines. Combination vaccines are those vaccines that contain multiple vaccine components. Conjugates or adjuvants in vaccines are not considered parts of the vaccine as defined above. See the reference table below.
According to ACIP, effective September 22, 2023, * Maternal RSV vaccine is recommended for pregnant people during 32 through 36 weeks of gestation. Be sure to indicate the appropriate diagnosis code for the weeks of gestation. (e.g. Z3A.32, Z3A.33, Z3A.34, Z3A.35, or Z3A.36). Refer to https://www.cdc.gov/vaccines/hcp/acip-recs/ for the latest ACIP recommendation.
Components of Common Pediatric Vaccines
Vaccine
Number of Vaccine Components
Immunization Adminstration Codes(s) Reported
Haemophilus influenzae type b - Hib
1
90460
Human Papillomavirus Virus
1
90460
Influenza
1
90460
Meningococcal
1
90460
Pneumococcal
1
90460
Rotavirus
1
90460
Haemophilus influenzae type b / Hepatitis B - (HepB-Hib)
2
90460, 90461
Tetanus and Diphtheria (Td)
2
90460, 90461
Diphtheria, Tetanus and Pertussis (DTaP)
3
90460, 90461 x 2
Tetanus, Diphtheria, and Pertussis (Tdap)
3
90460, 90461 x 2
Haemophilus influenzae type b - Hib
1
90460
Diphtheria, Tetanus and Pertussis (DTaP) / Polio - (DTaP-IPV)
4
90460, 90461 x 3
Diphtheria, Tetanus and Pertussis (DTaP) / Polio / Haemophilus influenzae type - (DTaP-Hib)
4
90460, 90461 x 3
Measles, Mumps, Rubella and Varicella (MMRV)
4
90460, 90461 x 3
Diphtheria, Tetanus and Pertussis (DTaP) / Hepatitis B / Polio - (DTaP-HepB-IPV)
5
90460, 90461 x 4
Diphtheria, Tetanus and Pertussis (DTaP) / Polio / Haemophilus influenzae type b - (DTaP-IPV/Hib)
5
90460, 90461 x 4
• Please be sure to use the most up-to-date industry-standard procedure, revenue, and diagnosis codes from the current CPT ®′′, HCPCS Level II, and ICD-10-CM manuals, as recommended by the American Medical Association (AMA), the Centers for Medicare & Medicaid Services (CMS), and the American Hospital Association.
♣ Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently.
♦ CPT, diagnosis codes and ACIP recommendations are subject to change and are used as reference examples only.
BCIS
Rev#:
Date:
Nature of Change:
3.04
10/02/2025
1100-1205563-1545950 Moved the new codes to be listed by type of vaccines.
3.03
10/01/2025
1100-1205563-1545950 The following codes and descriptions have been added: 90624 Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y-tetanus toxoid carrier, and Men B-FHbp, for intramuscular use, Meningococcal 90382 Respiratory syncytial virus, monoclonal antibody, seasonal dose, 0.7 mL, for intramuscular use, Respiratory Syncytial Virus (RSV)
3.02
09/11/2025
1100-1205556-1514650 The following code and description has been added to the vaccine codes list: COVID-19 - Moderna: 91323 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 10 mcg/0.2 mL dosage, for intramuscular use
3.01
06/16/2025
The following codes were added to the Vaccine Codes list:
90593 Chikungunya virus vaccine, recombinant, for intramuscular use
90683 Respiratory syncytial virus vaccine, mRNA lipid nanoparticles, for intramuscular use
90690 Typhoid vaccine, live, oral
3.0
03/20/2025
1100-1205514-1283650 Added: 90684 Pneumococcal conjugate vaccine, 21 valent (PCV21), for intramuscular use
Few minor edits adding "Long" to Description column for both tables (Vaccine Codes (Alphabetically ordered by Vaccine) Table and Vaccine Administration Code Table Removing Inactivated in Inactivated Influenza and added RSV to Respiratory Syncytial Virus under the Vaccine column in Vaccine Codes (Alphabetically ordered by Vaccine) Table
2.25 (v36)
10/13/2023
Replaced Vaccine Codes (Alphabetically ordered by Vaccine) Table - multi changes to Code, Description and Vaccine column Replaced Immunization Administration Table with Vaccine Administration Code Table - multi changes to Code, Description and Used for column
2.24 (v35)
10/11/2023
Updated Vaccine Codes Table: moved codes around to list them in alphabetical order by vaccines Added Under Immunization Administration Table codes 96380 & 96381 Claim Billing Examples (Added Example 3) Added information on last bullet point under Additional Billing Information
2.23 (v34)
10/03/2023
Added *Maternal to the description for codes 90380 and 990381. Added the following bullet to the Additional Billing Information section:
According to ACIP, effective September 22, 2023, *Maternal RSV vaccine is recommended for pregnant people during a specific week of gestation. Be sure to indicate the appropriate diagnosis code for the weeks of gestation.
2.22 (v33)
09/27/2023
Information regarding the COVID-19 Vaccine and Vaccine Administration codes were updated. The following vaccine codes were removed:
A note was added regarding the original vaccines. Asterisk removed from the following codes and description modified if applicable: 91303, 91304, 91312, 91313, 91314, 91315, 0031A, 0034A, 0041A, 0042A, 0044A, 0124A, 0134A, 0144A, 0154A, 0164A, 0173A, 0174A Added codes: 0121A, 0141A, 0142A, 0151A, 0171A, 0172A
2.17 (v28)
04/17/2023
The following have been posted:
*0164A IMMUNIZATION ADMIN BVL BOOSTER Moderna Bivalent Booster (Pediatric Use Only – 6 months through 5 years of age) *0173A IMMUNIZATION ADMIN 3RD DOSE Pfizer-BioNTech Bivalent Administration code (Pediatric Use Only – 6 months through 4 years of age) *0174A IMMUNIZATION ADMIN BVL BOOSTER Pfizer-BioNTech Bivalent Booster (Pediatric Use Only – 6 months through 4 years of age)
2.16 (v27)
10/27/2022
The following has been posted:
*0044A IMMUNIZATION ADMIN BOOSTER DOSE Novavax
2.15 (v26)
10/17/2022
The following revisions were posted:
Vaccine Codes section, under *91311, age criteria has changed from 4 => 5 years old. Immunization Administration section, the 3rd column under rows *0111A, *0112A, *0113A, age criteria has changed from 4 => 5 years old.
2.14 (v25)
10/14/2022
The following codes were added:
*91314 SARCOV2 VACCINE BIVALENT 25 MCG/0.25 ML IM USE Coronavirus vaccine – Moderna (Pediatric Use Only – 6 years through 11 years of age) *91315 SARCOV2 VACCINE BIVALENT 10 MCG/0.2 ML IM USE Coronavirus vaccine – Pfizer-BioNTech (Pediatric Use Only – 5 years through 11 years of age) *0144A IMMUNIZATION ADMIN BVL BOOSTER Moderna Bivalent Booster (Pediatric Use Only – 6 years through 11 years of age) *0154A IMMUNIZATION ADMIN BVL BOOSTER Pfizer-BioNTech Bivalent Booster (Pediatric Use Only – 5 years through 11 years of age)
2.13 (v24)
09/08/2022
The following vaccine codes were added:
*91312 SARSCOV2 BVL VACCINE 30 MCG/0.3 ML IM USE Coronavirus bivalent booster vaccine – Pfizer-BioNTech *91313 SARSCOV2 BVL VACCINE 50 MCG/0.5 ML IM USE Coronavirus bivalent booster vaccine – Moderna *0124A IMMUNIZATION ADMIN BVL BOOSTER Pfizer-BioNTech Bivalent Booster *0134A IMMUNIZATION ADMIN BVL BOOSTER Moderna Bivalent Booster
The following vaccine name has been updated: Pfizer-BioNTech COVID-19 Vaccine (Pediatric Use Only – 5 through 11 years of age) The following administration codes have been added: Pfizer-BioNTech COVID-19 Vaccine (Pediatric Use Only – 6 months through 4 years of age): 0081A (1st Dose), 0082A (2nd Dose), 0083A (3rd Dose) Moderna COVID-19 Vaccine (Pediatric Use Only – 6 months through 4 years of age): 0111A (1st Dose), 0112A (2nd Dose)
2.10 (v21)
06/22/2022
The following code has been updated:
*91307 SARSCOV2 VACCINE 10 MCG/0.2 ML IM USE Coronavirus vaccine – Pfizer-BioNTech (Pediatric Use Only – 5 through 11 years of age)
The following code has been added:
*91308 SARSCOV2 VACCINE 3 MCG/0.2 ML IM USE Coronavirus vaccine – Pfizer-BioNTech (Pediatric Use Only – 6 months through 4 years of age) *91311 SARSCOV2 VACCINE .25 MCG/0.25 ML IM USE Coronavirus vaccine – Moderna (Pediatric Use Only – 6 months through 4 years of age)